ATE306498T1 - Von zellen präsentierte peptide - Google Patents

Von zellen präsentierte peptide

Info

Publication number
ATE306498T1
ATE306498T1 AT01962874T AT01962874T ATE306498T1 AT E306498 T1 ATE306498 T1 AT E306498T1 AT 01962874 T AT01962874 T AT 01962874T AT 01962874 T AT01962874 T AT 01962874T AT E306498 T1 ATE306498 T1 AT E306498T1
Authority
AT
Austria
Prior art keywords
peptides
cells
determination
peptides presented
relates
Prior art date
Application number
AT01962874T
Other languages
English (en)
Inventor
Francis J Carr
Graham Carter
Koen Hellendoorn
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE306498T1 publication Critical patent/ATE306498T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT01962874T 2000-08-03 2001-07-26 Von zellen präsentierte peptide ATE306498T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0018901.9A GB0018901D0 (en) 2000-08-03 2000-08-03 Peptides presented by cells
PCT/EP2001/008625 WO2002012899A2 (en) 2000-08-03 2001-07-26 Peptides presented by cells

Publications (1)

Publication Number Publication Date
ATE306498T1 true ATE306498T1 (de) 2005-10-15

Family

ID=9896790

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01962874T ATE306498T1 (de) 2000-08-03 2001-07-26 Von zellen präsentierte peptide

Country Status (20)

Country Link
US (1) US20030171290A1 (de)
EP (1) EP1305343B1 (de)
JP (1) JP2004506202A (de)
KR (1) KR20030037272A (de)
CN (1) CN1511164A (de)
AT (1) ATE306498T1 (de)
AU (1) AU2001283958A1 (de)
BR (1) BR0112925A (de)
CA (1) CA2417767A1 (de)
CZ (1) CZ2003464A3 (de)
DE (1) DE60114018T2 (de)
GB (1) GB0018901D0 (de)
HU (1) HUP0301581A2 (de)
MX (1) MXPA03000901A (de)
NO (1) NO20030495D0 (de)
PL (1) PL358874A1 (de)
RU (1) RU2003105806A (de)
SK (1) SK1982003A3 (de)
WO (1) WO2002012899A2 (de)
ZA (1) ZA200301637B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1332371A2 (de) * 2000-09-18 2003-08-06 Genzyme Corporation Verfahren zur identifiezierung von antikörpernzielen basierend auf massenspektrometrie (maldi-tof)
ATE386937T1 (de) * 2001-06-19 2008-03-15 Suntory Ltd Verfahren zur analyse eines in der zelle auftretenden proteins oder einer mit dem protein wechselwirkenden substanz
US20070014807A1 (en) * 2003-09-03 2007-01-18 Maida Anthony E Iii Multiplex vaccine
NZ546173A (en) 2003-10-16 2009-04-30 Micromet Ag Multispecific deimmunized CD3-binders
EP1982176A1 (de) * 2006-01-30 2008-10-22 Dako Denmark A/S Quantifizierung antigenspezifischer t-zellen in vollblut mit hoher geschwindigkeit mittels durchflusszytometrie
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2167537A2 (de) 2007-07-03 2010-03-31 Dako Denmark A/S Zusammengestellte verfahren für die analyse und sortierung von proben
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
US10722562B2 (en) * 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
EP2496257A4 (de) 2009-11-05 2013-02-27 Cephalon Australia Pty Ltd Behandlung von krebs mit mutierten kras- oder braf-genen
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
KR102220382B1 (ko) * 2013-05-13 2021-02-25 셀렉티스 면역요법을 위한 매우 활성인 ｔ 세포를 조작하는 방법
PE20181535A1 (es) * 2015-12-16 2018-09-26 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno
JP2019528674A (ja) * 2016-09-30 2019-10-17 セレックス ライフ サイエンシズ，インコーポレーテッド タンパク質をロードしたエキソソームを含む組成物、並びにその調製及び送達のための方法
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
AU2018373154A1 (en) 2017-11-22 2020-07-02 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512624A (ja) * 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
EP1051432B1 (de) * 1998-12-08 2007-01-24 Biovation Limited Verfahren zur verminderung der immunogenität von proteinen
AU4676500A (en) * 1999-04-28 2000-11-10 Northwestern University Localization of major peptide autoepitopes for nucleosome specific t cells of systemic lupus erythematosus

Also Published As

Publication number Publication date
GB0018901D0 (en) 2000-09-20
KR20030037272A (ko) 2003-05-12
BR0112925A (pt) 2003-08-26
CZ2003464A3 (cs) 2003-06-18
RU2003105806A (ru) 2004-07-20
JP2004506202A (ja) 2004-02-26
NO20030495L (no) 2003-01-31
DE60114018T2 (de) 2006-06-29
WO2002012899A2 (en) 2002-02-14
EP1305343B1 (de) 2005-10-12
WO2002012899A3 (en) 2002-11-07
SK1982003A3 (en) 2003-08-05
CN1511164A (zh) 2004-07-07
AU2001283958A1 (en) 2002-02-18
NO20030495D0 (no) 2003-01-31
ZA200301637B (en) 2004-02-03
CA2417767A1 (en) 2002-02-14
HUP0301581A2 (hu) 2003-08-28
US20030171290A1 (en) 2003-09-11
MXPA03000901A (es) 2003-06-24
DE60114018D1 (de) 2006-02-23
PL358874A1 (en) 2004-08-23
EP1305343A2 (de) 2003-05-02

Similar Documents

Publication Publication Date Title
ATE306498T1 (de) Von zellen präsentierte peptide
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
AR038568A1 (es) Anticuerpos anti-a beta y su uso
CY1111006T1 (el) Εκριμματαση ασθενειας alzheimer
WO2003106657A3 (en) NUCLEOTIDE SEQUENCES AND AMINO ACID SEQUENCES WISE / SOST
WO2006069203A3 (en) Methods for proteomic profiling using non-natural amino acids
NO331199B1 (no) Fremgangsmåter for fremvisning av (poly)peptider/proteiner på bakteriofagpartikler via disulfid bindinger, nukleinsyresekvens, vektor, vertscelle, modifiserte varianter av proteiner, bakteriofagpartikkel og variert samling av bakteriofagpartikler.
BR0211199A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
WO2002002783A3 (en) Expression vectors
WO2004024750A3 (en) Cd44-binding ligands
AU3217100A (en) Methods of use of a novel lysyl oxidase-related protein
BR9811675A (pt) Genes isolados para proteìna da membrana de célula dentrìtica
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
DE60034966D1 (de) Auswertung von biologischen mitteln in lebenden zielzellen
BR9815788A (pt) Proteìna quimérica, ácido nucleico isolado, célula recombinante, processos para produzir uma proteìna quimérica, e para obter uma proteìna quimérica, produto, e, ensaio para triar uma sequência amino ácida quanto à capacidade de melhorar a dobragem de um precusor de insulina
WO2001053531A3 (en) Osteoarthritis tissue derived nucleic acids, polypeptides, vectors, and cells
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
WO2004050870A3 (en) Genetic switches for the detection of fusion proteins
SE9701228D0 (sv) Rekombinanta protein-C-och protein-S-varianter
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
BRPI0308978B8 (pt) fragmentos de peptídeos, e, composições imunogênicas
ATE338764T1 (de) Vorrichtung von peptid- oder proteindarstellung, verfahren zu deren herstellung und deren verwendung
WO2003099209A3 (en) Compositions and methods for screening and identifying anti-hcv agents
WO2003025197A3 (en) Mutant sh3-binding protein compositions and methods
WO2001018212A3 (en) Mycobacterium paratuberculosis-specific antigens and their diagnostic uses

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties